J. Terrasa

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: This dual treatment policy is feasible in a multicenter setting and preserves 70% of patients from adjuvant chemotherapy and single-agent carboplatin is effective in reducing the relapse rate in patients with high-risk stage I seminoma.

TL;DR: Long-term follow-up confirms the risk-adapted approach as an effective option for patients with stage I seminoma, and the pattern of relapses after adjuvant chemotherapy is similar to that observed following surveillance.

TL;DR: The BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible and it is expected that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches.

TL;DR: Testicular cancer represents the most common malignancy in males aged 15–34 years and is considered a model of curable neoplasm, and maintaining success, reducing treatment burden, and focusing on survivorship are then key objectives.